The University of Chicago Header Logo

Connection

Richard Schilsky to Breast Neoplasms

This is a "connection" page, showing publications Richard Schilsky has written about Breast Neoplasms.
Connection Strength

1.511
  1. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb; 8:e2300513.
    View in: PubMed
    Score: 0.314
  2. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 08 01; 39(22):2443-2451.
    View in: PubMed
    Score: 0.258
  3. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 12; 15(6):733-741.
    View in: PubMed
    Score: 0.252
  4. Clinical trials in the era of personalized oncology. CA Cancer J Clin. 2011 Nov-Dec; 61(6):365-81.
    View in: PubMed
    Score: 0.134
  5. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406.
    View in: PubMed
    Score: 0.056
  6. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol. 1996 Nov; 14(11):3000-8.
    View in: PubMed
    Score: 0.047
  7. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. J Clin Oncol. 2016 11 10; 34(32):3872-3879.
    View in: PubMed
    Score: 0.047
  8. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol. 1995 Mar; 13(3):741-7.
    View in: PubMed
    Score: 0.042
  9. Phase II study of echinomycin in patients with advanced breast cancer: a report of Cancer and Leukemia Group B protocol 8641. Invest New Drugs. 1991 Aug; 9(3):269-72.
    View in: PubMed
    Score: 0.033
  10. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care. 2008 Mar; 46(3):303-8.
    View in: PubMed
    Score: 0.026
  11. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006 Sep 20; 98(18):1335-8.
    View in: PubMed
    Score: 0.024
  12. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005 Jul 20; 97(14):1080-3.
    View in: PubMed
    Score: 0.022
  13. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005 Apr 01; 23(10):2191-200.
    View in: PubMed
    Score: 0.021
  14. Insulin effects on methotrexate polyglutamate synthesis and enzyme binding in cultured human breast cancer cells. Cancer Chemother Pharmacol. 1985; 15(3):272-7.
    View in: PubMed
    Score: 0.021
  15. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83.
    View in: PubMed
    Score: 0.018
  16. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15; 21(8):1431-9.
    View in: PubMed
    Score: 0.018
  17. Synthesis, binding and intracellular retention of methotrexate polyglutamates by cultured human breast cancer cells. Adv Exp Med Biol. 1983; 163:247-57.
    View in: PubMed
    Score: 0.018
  18. Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories. Clin Cancer Res. 2002 May; 8(5):943-8.
    View in: PubMed
    Score: 0.017
  19. Characteristics of membrane transport of methotrexate by cultured human breast cancer cells. Biochem Pharmacol. 1981 Jun 15; 30(12):1537-42.
    View in: PubMed
    Score: 0.016
  20. High-pressure liquid chromatography analysis of methotrexate polyglutamates in cultured human breast cancer cells. Biochem Pharmacol. 1981 Jun 01; 30(11):1387-90.
    View in: PubMed
    Score: 0.016
  21. Pharmacology and clinical status of capecitabine. Oncology (Williston Park). 2000 Sep; 14(9):1297-306; discussion 1309-11.
    View in: PubMed
    Score: 0.015
  22. Methotrexate polyglutamate synthesis by cultured human breast cancer cells. Proc Natl Acad Sci U S A. 1980 May; 77(5):2919-22.
    View in: PubMed
    Score: 0.015
  23. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809.
    View in: PubMed
    Score: 0.010
  24. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol. 1994 Dec; 12(12):2743-50.
    View in: PubMed
    Score: 0.010
  25. Prospects for fertility after cancer chemotherapy. Semin Oncol. 1992 Oct; 19(5):597-604.
    View in: PubMed
    Score: 0.009
  26. Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B. Cancer. 1991 Oct 15; 68(8):1696-8.
    View in: PubMed
    Score: 0.008
  27. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011 Mar; 47(5):683-9.
    View in: PubMed
    Score: 0.008
  28. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Feb 10; 27(5):812-26.
    View in: PubMed
    Score: 0.007
  29. Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. Semin Oncol. 2008 Oct; 35(5):470-83.
    View in: PubMed
    Score: 0.007
  30. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2007 Jan 01; 25(1):146-62.
    View in: PubMed
    Score: 0.006
  31. The synthesis and retention of methotrexate polyglutamates in cultured human breast cancer cells. Ann N Y Acad Sci. 1982 Dec 10; 397:184-92.
    View in: PubMed
    Score: 0.005
  32. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest. 1982 Aug; 70(2):351-60.
    View in: PubMed
    Score: 0.004
  33. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report. Invest New Drugs. 1990 May; 8(2):221-6.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.